+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Report Package: Hot targets for Empowered Antibody and Cell Therapy Technologies

  • ID: 3987826
  • Report
  • December 2016
  • Region: Global
  • 202 Pages
  • La Merie Publishing

This package contains three reports analyzing:

  • BCMA,
  • CD123 and
  • CD22

As versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

  • Fc-Engineered Antibodies;
  • Radioimmunotherapy;
  • Immunotoxins;
  • Antibody-Drug Conjugates;
  • T-Cell Redirecting Bispecific Antibodies;
  • Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss:

  • Target background, scientific rationale & expression profiles;
  • Preclinical proof-of-concept;
  • Clinical experience;
  • Competitive landscape;
  • Drug or cell therapy profiles;
  • Company profiles.
Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

B-Cell Maturation Antigen (BCMA): Hot target for Emerging Treatment Modalities

CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics

Detailed report descriptions and tables of from the reports can be found on the respective product pages listed in the `Also Available` section below.
Note: Product cover images may vary from those shown

Report 1:
B-Cell Maturation Antigen (BCMA): Hot target for Emerging Treatment Modalities

1. Target Background
2. Target Antigen Expression Profile
3. Preclinical Proof-of-Concept
4. Clinical Indications & Treatment Options
5. Clinical Experience with BCMA-Targeted Treatment Modalities
6. Treatment Modalities & Competitive Landscape

  •  Drug & Cell Therapy Candidate Profiles
  •  CAR T-Cells
  •  Antibody-Drug Conjugate (ADC)
  •  T-Cell Redirecting Antibodies

7. Company Profiles
8. References

Report 2:
CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

1. Target Background & Scientific Rationale
2. Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
3. Clinical Experience with CD123-Targeted Treatment Modalities
4. Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
5. Competitive Landscape
6. Profiles of Anti-CD123 Immunotherapeutics:

  • Immunotoxins
  • Naked Antibody
  • Fc-Engineered Antibodies
  • Antibody-Drug Conjugates
  • T-Cell Redirecting Bispecific Antibodies
  • Anti-CD123 CAR T-Cells

7. Company Profiles
8. References
9. ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

Report 3:
CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics

1. Target Background & Scientific Rationale
2. Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
3. Competitive Landscape
4. Profiles of Anti-CD22 Immunotherapeutics

  • Naked antibodies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and
  • Chimeric Antigen Receptor (CAR) T-Cells.

5. Profiles of Companies with CD22-Targeted Immunotherapeutics
6. References
7. ADDENDUM: Competitor Analysis of CD22-Targeted Immunotherapeutics

Note: Product cover images may vary from those shown
Adroll
adroll